# Index

| Acetyl choline | 202 |
| Activated protein C (APC) | 4 |
| Activin-like kinase-type 1 (Alk-1) | 91 |
| Acute lung injury (ALI) | 5 |
| Acute physiology and chronic health evaluation (APACHE) | 4, 6 |
| Adult respiratory distress syndrome (ARDS) | 5 |
| Advanced glycation end product (AGE) | 161–163 |
| AGE-R3 | 162 |
| Akt (protein kinase B) | 71 |
| Allopurinol | 55 |
| AMP kinase | 71 |
| Angiogenesis | 68, 149, 150 |
| Angiopoietin-1 (Ang-1) | 6, 72, 92, 93 |
| Ang1-Tie2 pathway | 92, 93 |
| Angiopoietin-2 (Ang-2) | 6 |
| Angiotensin | 49, 105 |
| Angiotensin converting enzyme inhibitor (ACEI) | 108 |
| Type 1 angiotensin II receptor (AT1R) | 108, 109 |
| Antioxidant supplementation | 57 |
| Antithrombin III (ATIII) | 3, 4 |
| Aorta, lesser (LC) and greater curvature (GC) | 177 |
| Apocynin | 56 |
| Apolipoprotein E knockout (apoE KO) mouse | 162, 166 |
| Apoptosis, endothelial | 7, 8 |
| Apoptosis signal-regulating kinase 1 (ASK1) signalosome | 142 |
| Artery/arteriole, role in blood pressure control | 16, 26 |
| Asymmetric dimethyl arginine (ADMA) | 45 |
| Atherosclerosis | 176–183, 201 |
| Initiation | 182 |
| Nascent lesion | 183 |
| Predisposition | 176–179 |
| Progression | 201 |
| Augmentation index | 210 |
| Bariatric surgery | 212 |
| Basal and stimulated blood flow | 206 |
| Blood pressure | 104 |
| Bone morphogenetic protein receptor 2 (BMPR2) | 90, 91 |
| Bradykinin | 71, 202 |
| Bromodeoxyuridine (BrdU) | 180 |
| Calmodulin (CaM) | 68 |
| Calmodulin-dependent kinase II (CaMKII) | 71 |
| Capillaries, role in leukocyte recruitment | 17 |
| Caspases, pro-apoptotic | 6, 8 |
| Caveolin | 67, 68 |
| CD11c-diphtheria toxin receptor (DTR) | 182 |
| Cell adhesion molecule | 17, 19, 21–27 |
| Clinical testing, atherosclerotic disease progression | 201 |
### Index

- **coagulation** 224
- **connexin** 20
- **coronary vascular dysfunction** 211
- **C-reactive protein (CRP)** 212
- **CX3CL1 (fraktalkine)** 181
- **cyclooxygenase (COX)** 106, 192–194
- **dendritic cell, resident intimal (RIDC)** 179–183
- **diabetes** 166
- **digital plethysmography** 210
- **CD11c-diphteria toxin receptor (DTR)** 182
- **dismutation** 39
- **disseminated intravascular coagulation (DIC)** 3
- **drotrecogin α** 4
- **early growth response gene-1 (EGR-1)** 2
- **edge-detection** 206
- **endogenous secretory RAGE (esRAGE)** 164
- **endothelium** 91
- **endothelial activation** 201
- **endothelial cell, signal transduction** 22, 27, 28
- **endothelial cell apoptosis** 89, 90
- **endothelial cell activation** 22, 24, 176
  - *in vitro* 22
  - *in vivo* 24
- **endothelial dysfunction** 45
- **endothelial heterogeneity** 15, 19, 22–28
  - *in quiescent condition* 19, 22
  - *in response to inflammation* 22–24, 26, 27
  - *in response to shear stress* 23
  - molecular basis 27, 28
- **endothelial nitric oxide synthase (eNOS)** 41, 45, 52, 53, 57, 65–74, 83, 178
  - expression 178
  - interacting protein 67
  - phosphorylation 70–73
  - uncoupled 52, 53, 57
- **endothelial permeability** 5
- **endothelial pharmacology** 18, 29
- **endothelial protein C receptor (EPCR)** 4
- **endothelin receptor antagonist (ERA)** 87
- **endothelin-1 (ET-1)** 82, 85
- **endothelin-A receptor** 212
- **endothelium, regenerated** 195
- **endothelium, role in inflammation** 16, 17
- **endothelium-dependent relaxing factor** 190
- **endothelium-derived hyperpolarizing factor (EDHF)** 86, 104
- **endothelium-derived relaxing factor** 104
- **endothelium-independent vasodilatation** 208
- **epicardial and microvascular function** 202
- **ER stress** 143, 144
- **E-selectin** 7, 17, 19, 24
- **extracellular matrix** 162
- **fas-associated death domain (FADD)** 8
- **flavin adenine dinucleotide (FAD)** 48
- **flow-mediated dilatation (FMD)** 203–208
- **fluid shear stress** 69
- **fms-related tyrosine kinase 1 (Flt-1, VEGFR2)** 6
- **fraktalkine** 181
- **geldanamycin** 69
- **gene expression, NF-κB priming in endothelial cell** 178
- **genetically modified mouse** 51, 162, 166
- **Gi protein-dependent pathway** 195
- **glomerular endothelial cell** 19, 22, 26–28
- **glyceryl trinitrate (GTN)** 208
- **guanylate cyclase** 69
- **Haber-Weiss/Fenton reaction** 43
- **90-kDa heat shock protein (Hsp90)** 67, 69
- **hemofiltration** 224
- **high-density lipoprotein (HDL)** 126
- **high-resolution ultrasound** 203
- **histamine** 69
- **hydrogen peroxide (H₂O₂)** 43, 46, 53
- **hydroxyl radical (OH•)** 43
- **hyperpolarization, endothelium-dependent** 192, 193
- **hypertension, systemic** 103–111
- **hypoension model in mouse** 51
inflammation induced vascular dysfunction 211
inflammatory angiogenesis 149, 150
inflammatory arteriogenesis 149
intercellular adhesion molecule-1 (ICAM-1)
  6, 7, 17, 19, 24
interleukin-1 (IL-1), endothelial activation
  2, 4, 22, 24
intermediate-conductance calcium-activated potassium channel (IK_{Ca}) 192
intravenously delivered immune globulin (IVIG) 223
ischaemia-reperfusion 212
junction protein 6, 7
junctional adhesion molecule (JAM) 7
kinase, as pharmacological target 28
kindling-bonfire hypothesis 51, 57
L-arginine 110
leukocyte adhesion 6, 124
leukocyte recruitment 16–18
leukocyte trafficking 6
lipid oxidation/peroxidation 44
lipopolysaccharide (LPS) 2, 4, 26
low-density lipoprotein (LDL) 195
manganese superoxide dismutase 56, 194
microcirculation 219
microenvironment, endothelial 15, 27
microparticle, endothelial, in sepsis 4, 5
mitochondrial matrix 56
mitochondrial respiratory chain 55
monocyte subpopulation 180
N-myristoylation 66
NADPH oxidase 47–53, 194
nitric oxide (NO) 5, 38–42, 82, 83, 104, 162, 164, 190, 193, 195
NO inhibitor, therapy 5
nitric oxide radical (NO•) 41, 42
nitric oxide synthase (NOS) 5, 40
endothelial, see endothelial nitric oxide synthase (eNOS)
nitric oxide synthase interacting protein (NOSIP) 67
nitric oxide synthase trafficker (NOSTRIN) 67
nitroxyl (HNO) 41
nitroxyl anion (NO–) 41
N-myristoylation 66
Nox protein 47, 48
nuclear factor (NF)-κB 2, 3, 194
expression 178
in endothelial activation 2, 3
occlusion, cuff position and duration of 208
oxidative stress 37, 144–146, 194, 195
palmitoylation 66
pathogen-associated molecular pattern (PAMP) 222, 223
periodontal therapy 212
peroxyl radical (ROO•) 44
peroxynitrite 42, 105
pertussis toxin sensitive 190, 195
phosphatidylserine 3
plasminogen activator inhibitor-1 (PAI-1) 4
plexiform lesion 94
postcapillary venule, role in leukocyte recruitment 17
progenitor cell therapy 94
prostacyclin 82, 84, 106, 192
protease-activated receptor-1 (PAR-1) 4
protein kinase A, B and G 71
protein oxidation 44
P-selectin 6, 7, 17, 19
psychophysiological mental stress testing 212
pulmonary arterial hypertension (PAH) 81, 82
pulmonary vascular endothelium 82
pulse amplitude tonometry (PAT) 211
pulse contour analysis (PCA) 210
pulse wave analysis (PWA) 210
pulse wave velocity 209
Index

radial artery tonometry 210
reactive hyperaemia 203, 211
reactive hyperaemia pulse amplitude tonometry (RH-PAT) 211
reactive nitrogen species (RNS) 40
reactive oxygen species (ROS) 38, 46, 162, 164, 165
receptor for advanced glycation end products (RAGE) 163–166
RAGE, endogenous secretory (esRAGE) 164
RAGE, soluble (sRAGE) 164, 165
reflection index 210
resident intimal dendritic cell (RIDC) 179–183
resuscitation 220
salbutamol 210
P-selectin 6, 7, 17, 19
sepsis, severe 1–5, 219
  definition 1
septic shock 2, 219
  definition 2
shear rate 207
shear stress 107, 206
signal transduction in endothelial cell 22, 28
small conductance calcium-activated potassium channel (SKCa) 192
smooth muscle cell (SMC) 104, 105, 107
  hyperpolarization 107
soluble guanylate cyclase (sGC) 105
soluble RAGE (sRAGE) 164, 165
sphingosine-1-phosphate 121–127
  angiogenesis 121
  endothelium 121
  inflammation 126
  leukocyte adhesion 124
  permeability 123
sphingosine-1-phosphate agonist 127
statin 110
steroid 226
strain-gauge plethysmography 202
substance P 202
superoxide anion 38, 39, 42, 43, 46, 49, 105
superoxide dismutase (SOD) 40, 105
systemic inflammatory shock syndrome (SIRS) 1
tetrahydrobiopterin (BH4) 45, 52, 54, 110
thrombomodulin (TM) 4
thromboxane A2 82, 85
thromboxane-prostanoid (TP) receptor 193
tissue factor 4, 88
tissue factor pathway inhibitor (TFPI) 3, 4
tissue-type plasminogen activator (tPA) 4
tocopheroxyl radical 58
toll-like receptor (TLR) 2
tumor microvasculature 70
tumor necrosis factor-α (TNF-α) 2, 4, 22, 24
tumor necrosis factor receptor 1 (TNFR1) signaling 138–142
tumor necrosis factor receptor 2 (TNFR2) signaling 137, 138, 149, 150
type 1 angiotensin II receptor (AT1R) 108, 109
urate 54
vascular cell adhesion molecule-1 (VCAM-1) 6, 7, 17, 19, 24, 176, 177, 180
VCAM-1 expression 176, 177
vascular dysfunction, inflammation induced 211
vascular endothelial growth factor (VEGF) 6, 18–20, 69, 70
  heterogeneity in expression 18–20
  role in leukocyte recruitment 18
VEGF receptor-2 (VEGFR-2) 6, 70
vascular permeability 65
vascular segment specificity 17
vasomotor tone, in sepsis 5
vessel wall, role in leukocyte recruitment 17
wall-tracking 206
xanthine oxidase (XO) 54, 57, 194
The PIR-Series
Progress in Inflammation Research

Homepage: www.birkhauser.ch

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:
T Cells in Arthritis, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
Medicinal Fatty Acids, J. Kremer (Editor), 1998
Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999
Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999
Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999
Apoptosis and Inflammation, J.D. Winkler (Editor), 1999
Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
Metalloproteinases as Targets for Anti-Inflammatory Drugs, K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000
Cellular Mechanisms in Airways Inflammation, C. Page, K. Banner, D. Spina (Editors), 2000
Inflammatory and Infectious Basis of Atherosclerosis, J.L. Mehta (Editor), 2001
Neuroinflammatory Mechanisms in Alzheimer’s Disease. Basic and Clinical Research, J. Rogers (Editor), 2001
Inflammation and Stroke, G.Z. Feuerstein (Editor), 2001
NMDA Antagonists as Potential Analgesic Drugs, D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002
Mechanisms and Mediators of Neuropathic pain, A.B. Malmberg, S.R. Chaplan (Editors), 2002
Bone Morphogenetic Proteins. From Laboratory to Clinical Practice, S. Vukicevic, K.T. Sampath (Editors), 2002
The Hereditary Basis of Allergic Diseases, J. Holloway, S. Holgate (Editors), 2002
Inflammation and Cardiac Diseases, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003
Mind over Matter – Regulation of Peripheral Inflammation by the CNS, M. Schäfer, C. Stein (Editors), 2003
Heat Shock Proteins and Inflammation, W. van Eden (Editor), 2003
Pharmacotherapy of Gastrointestinal Inflammation, A. Guglietta (Editor), 2004
Arachidonate Remodeling and Inflammation, A.N. Fonteh, R.L. Wykle (Editors), 2004
Recent Advances in Pathophysiology of COPD, P.J. Barnes, T.T. Hansel (Editors), 2004
Cytokines and Joint Injury, W.B. van den Berg, P. Miossec (Editors), 2004
Cancer and Inflammation, D.W. Morgan, U. Forssmann, M.T. Nakada (Editors), 2004
Bone Morphogenetic Proteins: Bone Regeneration and Beyond, S. Vukicevic, K.T. Sampath (Editors), 2004
Antibiotics as Anti-Inflammatory and Immunomodulatory Agents, B.K. Rubin, J. Tamaoki (Editors), 2005
Regulatory T-Cells in Inflammation, L. Taams, A.N. Akbar, M.H.M Wauben (Editors), 2005
Sodium Channels, Pain, and Analgesia, K. Coward, M. Baker (Editors), 2005
Turning up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation, A.B Malmberg, K.R. Bley (Editors), 2005
The NPY Family of Peptides in Immune Disorders, Inflammation, Angiogenesis and Cancer, Z. Zukowska, G.Z. Feuerstein (Editors), 2005
Toll-like Receptors in Inflammation, L.A.J. O’Neill, E. Brint (Editors), 2005
Complement and Kidney Disease, P.F. Zipfel (Editor), 2006
Chemokine Biology – Basic Research and Clinical Application, Volume 1: Immunobiology of Chemokines, B. Moser, G.L. Letts, K. Neote (Editors), 2006
The Hereditary Basis of Rheumatic Diseases, R. Holmdahl (Editor), 2006
Lymphocyte Trafficking in Health and Disease, R. Badolato, S. Sozzani (Editors), 2006
Adhesion Molecules: Function and Inhibition, K. Ley (Editor), 2007
The Immune Synapse as a Novel Target for Therapy, L. Graca (Editor), 2008
The Resolution of Inflammation, A.G. Rossi, D.A. Sawatzky (Editors), 2008
Bone Morphogenic Proteins: From Local to Systemic Therapeutics, S. Vukicevic, K.T. Sampath (Editors), 2008
Angiogenesis in Inflammation: Mechanisms and Clinical Correlates, M.P. Seed, D.A. Walsh (Editors), 2008
Matrix Metalloproteinases in Tissue Remodelling and Inflammation, V. Lagente, E. Boichot (Editors), 2008
Microarrays in Inflammation, A. Bosio, B. Gerstmayer (Editors), 2009
Th 17 Cells: Role in Inflammation and Autoimmune Disease, B. Ryffel, F. Di Padova (Editors), 2009
New Therapeutic Targets in Rheumatoid Arthritis, P.P. Tak (Editor), 2009
The Hygiene Hypothesis and Darwinian Medicine, G.A.W. Rook (Editor), 2009
Occupational Asthma, T. Sigsgaard, D. Heederik (Editors), 2010
Inflammatory Cardiomyopathy (DCMi) – Pathogenesis and Therapy, H.P. Schulteiss, M. Noutsias (Editors), 2010